A phase 1b dose-escalation/expansion study of BET inhibitor RO6870810 in patients with advanced multiple myeloma

A phase 1b dose-escalation/expansion study of BET inhibitor RO6870810 in patients with advanced multiple myeloma

Bibliographic Details
Main Authors: Karthik Ramasamy, Ajay Nooka, Hang Quach, Myo Htut, Rakesh Popat, Michaela Liedtke, Sascha A. Tuchman, Jacob Laubach, Cristina Gasparetto, Asher Chanan-Khan, Mark Hertzberg, Mark deMario, Eveline Nueesch, Evelyne Chesne, Izolda Franjkovic, Katharina Lechner, Martin Kornacker, Hearn Jay Cho
Format: Article
Language:English
Published: Nature Publishing Group 2021-09-01
Series:Blood Cancer Journal
Online Access:https://doi.org/10.1038/s41408-021-00545-w
id doaj-10c2cc1e770743f2a87f66ba38a6b379
record_format Article
spelling doaj-10c2cc1e770743f2a87f66ba38a6b3792021-09-05T11:49:43ZengNature Publishing GroupBlood Cancer Journal2044-53852021-09-011191310.1038/s41408-021-00545-wA phase 1b dose-escalation/expansion study of BET inhibitor RO6870810 in patients with advanced multiple myelomaKarthik Ramasamy0Ajay Nooka1Hang Quach2Myo Htut3Rakesh Popat4Michaela Liedtke5Sascha A. Tuchman6Jacob Laubach7Cristina Gasparetto8Asher Chanan-Khan9Mark Hertzberg10Mark deMario11Eveline Nueesch12Evelyne Chesne13Izolda Franjkovic14Katharina Lechner15Martin Kornacker16Hearn Jay Cho17Department of Haematology, Oxford University Hospital, NHS TrustWinship Cancer Institute, Emory UniversityUniversity of Melbourne, St. Vincent’s HospitalCity of Hope Comprehensive Cancer CenterUniversity College London Hospitals, NHS Foundation TrustStanford University Cancer CenterDivision of Hematology, Lineberger Comprehensive Cancer Center, University of North CarolinaDept. of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical SchoolDepartment of Medicine, Duke Univ. Medical CenterDivision of Hematology and Medical Oncology, Mayo ClinicDepartment of Clinical Haematology, Prince of Wales HospitalRoche Pharma Research and Early DevelopmentRoche Innovation Center Basel, Roche Pharma Research and Early DevelopmentRoche Innovation Center Basel, Roche Pharma Research and Early DevelopmentRoche Innovation Center Munich, Roche Pharma Research and Early DevelopmentRoche Innovation Center Munich, Roche Pharma Research and Early DevelopmentRoche Innovation Center Basel, Roche Pharma Research and Early DevelopmentTisch Cancer Institute, Icahn School of Medicine at Mount Sinaihttps://doi.org/10.1038/s41408-021-00545-w
collection DOAJ
language English
format Article
sources DOAJ
author Karthik Ramasamy
Ajay Nooka
Hang Quach
Myo Htut
Rakesh Popat
Michaela Liedtke
Sascha A. Tuchman
Jacob Laubach
Cristina Gasparetto
Asher Chanan-Khan
Mark Hertzberg
Mark deMario
Eveline Nueesch
Evelyne Chesne
Izolda Franjkovic
Katharina Lechner
Martin Kornacker
Hearn Jay Cho
spellingShingle Karthik Ramasamy
Ajay Nooka
Hang Quach
Myo Htut
Rakesh Popat
Michaela Liedtke
Sascha A. Tuchman
Jacob Laubach
Cristina Gasparetto
Asher Chanan-Khan
Mark Hertzberg
Mark deMario
Eveline Nueesch
Evelyne Chesne
Izolda Franjkovic
Katharina Lechner
Martin Kornacker
Hearn Jay Cho
A phase 1b dose-escalation/expansion study of BET inhibitor RO6870810 in patients with advanced multiple myeloma
Blood Cancer Journal
author_facet Karthik Ramasamy
Ajay Nooka
Hang Quach
Myo Htut
Rakesh Popat
Michaela Liedtke
Sascha A. Tuchman
Jacob Laubach
Cristina Gasparetto
Asher Chanan-Khan
Mark Hertzberg
Mark deMario
Eveline Nueesch
Evelyne Chesne
Izolda Franjkovic
Katharina Lechner
Martin Kornacker
Hearn Jay Cho
author_sort Karthik Ramasamy
title A phase 1b dose-escalation/expansion study of BET inhibitor RO6870810 in patients with advanced multiple myeloma
title_short A phase 1b dose-escalation/expansion study of BET inhibitor RO6870810 in patients with advanced multiple myeloma
title_full A phase 1b dose-escalation/expansion study of BET inhibitor RO6870810 in patients with advanced multiple myeloma
title_fullStr A phase 1b dose-escalation/expansion study of BET inhibitor RO6870810 in patients with advanced multiple myeloma
title_full_unstemmed A phase 1b dose-escalation/expansion study of BET inhibitor RO6870810 in patients with advanced multiple myeloma
title_sort phase 1b dose-escalation/expansion study of bet inhibitor ro6870810 in patients with advanced multiple myeloma
publisher Nature Publishing Group
series Blood Cancer Journal
issn 2044-5385
publishDate 2021-09-01
url https://doi.org/10.1038/s41408-021-00545-w
work_keys_str_mv AT karthikramasamy aphase1bdoseescalationexpansionstudyofbetinhibitorro6870810inpatientswithadvancedmultiplemyeloma
AT ajaynooka aphase1bdoseescalationexpansionstudyofbetinhibitorro6870810inpatientswithadvancedmultiplemyeloma
AT hangquach aphase1bdoseescalationexpansionstudyofbetinhibitorro6870810inpatientswithadvancedmultiplemyeloma
AT myohtut aphase1bdoseescalationexpansionstudyofbetinhibitorro6870810inpatientswithadvancedmultiplemyeloma
AT rakeshpopat aphase1bdoseescalationexpansionstudyofbetinhibitorro6870810inpatientswithadvancedmultiplemyeloma
AT michaelaliedtke aphase1bdoseescalationexpansionstudyofbetinhibitorro6870810inpatientswithadvancedmultiplemyeloma
AT saschaatuchman aphase1bdoseescalationexpansionstudyofbetinhibitorro6870810inpatientswithadvancedmultiplemyeloma
AT jacoblaubach aphase1bdoseescalationexpansionstudyofbetinhibitorro6870810inpatientswithadvancedmultiplemyeloma
AT cristinagasparetto aphase1bdoseescalationexpansionstudyofbetinhibitorro6870810inpatientswithadvancedmultiplemyeloma
AT asherchanankhan aphase1bdoseescalationexpansionstudyofbetinhibitorro6870810inpatientswithadvancedmultiplemyeloma
AT markhertzberg aphase1bdoseescalationexpansionstudyofbetinhibitorro6870810inpatientswithadvancedmultiplemyeloma
AT markdemario aphase1bdoseescalationexpansionstudyofbetinhibitorro6870810inpatientswithadvancedmultiplemyeloma
AT evelinenueesch aphase1bdoseescalationexpansionstudyofbetinhibitorro6870810inpatientswithadvancedmultiplemyeloma
AT evelynechesne aphase1bdoseescalationexpansionstudyofbetinhibitorro6870810inpatientswithadvancedmultiplemyeloma
AT izoldafranjkovic aphase1bdoseescalationexpansionstudyofbetinhibitorro6870810inpatientswithadvancedmultiplemyeloma
AT katharinalechner aphase1bdoseescalationexpansionstudyofbetinhibitorro6870810inpatientswithadvancedmultiplemyeloma
AT martinkornacker aphase1bdoseescalationexpansionstudyofbetinhibitorro6870810inpatientswithadvancedmultiplemyeloma
AT hearnjaycho aphase1bdoseescalationexpansionstudyofbetinhibitorro6870810inpatientswithadvancedmultiplemyeloma
AT karthikramasamy phase1bdoseescalationexpansionstudyofbetinhibitorro6870810inpatientswithadvancedmultiplemyeloma
AT ajaynooka phase1bdoseescalationexpansionstudyofbetinhibitorro6870810inpatientswithadvancedmultiplemyeloma
AT hangquach phase1bdoseescalationexpansionstudyofbetinhibitorro6870810inpatientswithadvancedmultiplemyeloma
AT myohtut phase1bdoseescalationexpansionstudyofbetinhibitorro6870810inpatientswithadvancedmultiplemyeloma
AT rakeshpopat phase1bdoseescalationexpansionstudyofbetinhibitorro6870810inpatientswithadvancedmultiplemyeloma
AT michaelaliedtke phase1bdoseescalationexpansionstudyofbetinhibitorro6870810inpatientswithadvancedmultiplemyeloma
AT saschaatuchman phase1bdoseescalationexpansionstudyofbetinhibitorro6870810inpatientswithadvancedmultiplemyeloma
AT jacoblaubach phase1bdoseescalationexpansionstudyofbetinhibitorro6870810inpatientswithadvancedmultiplemyeloma
AT cristinagasparetto phase1bdoseescalationexpansionstudyofbetinhibitorro6870810inpatientswithadvancedmultiplemyeloma
AT asherchanankhan phase1bdoseescalationexpansionstudyofbetinhibitorro6870810inpatientswithadvancedmultiplemyeloma
AT markhertzberg phase1bdoseescalationexpansionstudyofbetinhibitorro6870810inpatientswithadvancedmultiplemyeloma
AT markdemario phase1bdoseescalationexpansionstudyofbetinhibitorro6870810inpatientswithadvancedmultiplemyeloma
AT evelinenueesch phase1bdoseescalationexpansionstudyofbetinhibitorro6870810inpatientswithadvancedmultiplemyeloma
AT evelynechesne phase1bdoseescalationexpansionstudyofbetinhibitorro6870810inpatientswithadvancedmultiplemyeloma
AT izoldafranjkovic phase1bdoseescalationexpansionstudyofbetinhibitorro6870810inpatientswithadvancedmultiplemyeloma
AT katharinalechner phase1bdoseescalationexpansionstudyofbetinhibitorro6870810inpatientswithadvancedmultiplemyeloma
AT martinkornacker phase1bdoseescalationexpansionstudyofbetinhibitorro6870810inpatientswithadvancedmultiplemyeloma
AT hearnjaycho phase1bdoseescalationexpansionstudyofbetinhibitorro6870810inpatientswithadvancedmultiplemyeloma
_version_ 1717813841470947328

Similar Items